MACC - Ongoing Studies and Trials

The MACC is actively recruiting participants for research projects to help us have a better understanding of dementia and cognitive decline. In the process, our participants also learn more about themselves and take an active role in the care of their own health and memory. Our studies are conducted under approved protocols that ensure the wellbeing, safety and privacy of our participants.

Read more about our SINGER and AHEAD studies, and do contact us if you are interested to join. You may take a quick memory screening test here to help us figure out which study would be the best fit for your cognition status.

SINGER study

SINGER is a two-year clinical trial that aims to evaluate whether multidomain lifestyle intervention is effective in reducing cognitive decline and physical frailty in at risk elderly in Singapore. Click here to read more about this study.

AHEAD study

The AHEAD Study tests whether intervening ahead of symptoms may prevent future memory loss and dementia. • The study looks at an investigational treatment aimed at delaying memory decline in people up to 20 years before the symptoms of Alzheimer’s disease appear.

The MACC has many years of experience in conducting a variety of projects and studies in cognitive decline and dementia. If you are interested in collaborating with us, please contact us. We are also providing coordinating and psychometric rating services for clinical studies and clinical trial, click here to see our services.

Below is the extensive list of our ongoing and completed clinical studies and clinical trials.

Clinical Research Studies

Ongoing

Improving the Diagnosis of Vascular Cognitive Impairment by a) Prospective Longitudinal Clinical Studies and b) Dementia Neuroimaging using Multi-Modal Magnetic Resonance and Retinal Imaging
Etiology of Cortical Cerebral Microinfarcts and Impact on Brain Function and Long Term Outcomes
Translational Research in Vascular Biomarkers of Dementia: Discovery, Validation and Assessment of Clinical Utility
The Assessment of cnm-positive Streptococcus mutans as the Risk for Cerebral Small Vessel Disease in Cognitively Impaired Patients
Associations of sleep and rhythm fragmentation with beta amyloid burden in older adults
The SINgapore GERiatric intervention study to reduce cognitive decline and physical frailty (SINGER) Study, biomarker and health service research analyses
CURATE.AI COR-Tx Trial for Post Brain Radiotherapy Patients

Completed Studies

A 78-Week NoninterventionalLongitudinal Study to Validate the Alzheimer’s Disease Assessment Scale –Cognitive Subscale (ADAS-Cog), Disability Assessment for Dementia (DAD), and Neuropsychological Test Battery (NTB) in Asian Subjects With Mild to Moderate Alzheimer’s Disease
Cognitive Outcome After STroke (COAST)
Translational Research in Dementia: Mechanisms of Diseases, Pathophysiology and Biomarker Discovery
The feasibility and validation of an informant-based cognitive screening instrument in the primary healthcare setting
Epidemiology of Dementia in Singapore : Ethnicity and Risk Factors
Retinal Imaging in Dementia
Cognitive Outcome After STroke -Extension (COAST-E)
An exploratory study to compare the differences in nutritional status between patients with mild and moderate Alzheimer’s disease (AD) and cognitively intact healthy people in an Asian population
Preclinical and clinical investigations of neurodegeneration and age-associated cognitive impairment Project V (Amyloid Brain and Retinal Imaging studies) –ABRI
PET amyloid-beta imaging in MCI and dementia subjects
A multi-national observational study to identify treatment discontinuation rate in de novo Alzheimer’s disease patient who is newly prescribed with donepezil (Aricept®) in Asia
SINgapore GERiatric intervention study to reduce physical frailty and cognitive decline (SINGER) Pilot Studies
Ocular Markers of Alzheimer’s Disease: OMEGA Study

Clinical Trials

Ongoing

A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to EvaluateEfficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer’s Disease and ElevatedAmyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer’s Disease and Intermediate Amyloid (A3 Trial).
A Phase III, 20-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Trial to Investigate the Efficacy and Safety of Daily Administration of Tricaprilin as AC-SD-03 in Subjects with Mild to Moderately Severe Probable Alzheimer’s Disease and Who are Noncarriers of the APOE4 allele
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer’s Disease
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Gantenerumab in Patients with Prodromal to Mild Alzheimer’s Disease
Tau-Positron emission tomography imaging and tau plasma biomarkers for the diagnosis of Alzheimer?s Disease
Preclinical and clinical investigations of neurodegeneration and age-associated cognitive impairment – NAV4694 for Amyloid Brain imaging, amyloid plasma biomarker and Retinal Imaging (NAV ABRI)

Completed Studies

Chinese Medicine Neuroaid Efficacy on Stroke recovery (CHIMES) Study
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 15-Month Trial of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Mild to Moderate Alzheimer’s Disease
Randomized, double-blind, parallel-group, placebo controlled study of Lu AE58054 in patients with mild-moderate Alzheimer’s disease treated with an acetylcholinesterase inhibitor; Phase 3
A multicenter, double-blind, placebo-controlled, randomized, parallel-group phase 3 Study to Evaluate the Safety and Efficacy of Masitinib in Patients With Mild to Moderate Alzheimer’s Disease
Randomised, double-blind, parallel-group, placebocontrolled study of Lu AE58054 in patients with mild-moderate Alzheimer’s disease treated with an acetylcholinesterase inhibitor; Study 3
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer’s Disease
Phase 1 Randomized, Double-blind, Dose Escalation Safety Study of MLC1501 in Healthy Subjects
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects with Alzheimer’s Disease
Chinese Medicine Neuroaid Efficacy on Stroke recovery Extenstion (CHIMES-E) Study
NEURoaid II (MLC 901) Assessment in Cognitively Impaired Not Demented Subjects (NEURITES)
An Open-Label. Extension Study of the Effects of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Alzheimer’s Disease or Behavioral Variant Frontotemporal Dementia
A Phase 3, double blind, randomized study of RVT-101 versus placebo when added to existing stable donepezil treatment in subjects with mild to moderate Alzheimer’s disease” RVT-101-3001
The Alzheimer’s disease THErapy with NEuroaid (ATHENE) Study : Assessing the Safety and Efficacy of Neuroaid II (MLC901) in patients with mild to moderate Alzheimer’s disease stable on Cholinesterase inhibitors or Memantine: A Randomized, double blind, placebo controlled trial